ATE483708T1 - Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase - Google Patents

Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase

Info

Publication number
ATE483708T1
ATE483708T1 AT05717953T AT05717953T ATE483708T1 AT E483708 T1 ATE483708 T1 AT E483708T1 AT 05717953 T AT05717953 T AT 05717953T AT 05717953 T AT05717953 T AT 05717953T AT E483708 T1 ATE483708 T1 AT E483708T1
Authority
AT
Austria
Prior art keywords
inhibitors
glycogen phosphorylase
pyrrolopyridine
carbonic acid
acid hydrazides
Prior art date
Application number
AT05717953T
Other languages
English (en)
Inventor
Stuart Bradley
Revathy Jeevaratnam
Thomas Krulle
Martin Procter
Robert Rowley
Gerard Thomas
Ana Valdes
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Application granted granted Critical
Publication of ATE483708T1 publication Critical patent/ATE483708T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05717953T 2004-03-08 2005-03-08 Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase ATE483708T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55125404P 2004-03-08 2004-03-08
PCT/GB2005/000885 WO2005085245A1 (en) 2004-03-08 2005-03-08 Pyrrolopyridine-2-carboxylic acid hydrazides

Publications (1)

Publication Number Publication Date
ATE483708T1 true ATE483708T1 (de) 2010-10-15

Family

ID=34919586

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05717953T ATE483708T1 (de) 2004-03-08 2005-03-08 Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase

Country Status (7)

Country Link
US (1) US7884112B2 (de)
EP (1) EP1725555B1 (de)
JP (1) JP2007527904A (de)
AT (1) ATE483708T1 (de)
DE (1) DE602005023965D1 (de)
ES (1) ES2353309T3 (de)
WO (1) WO2005085245A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5277407B2 (ja) * 2007-12-14 2013-08-28 名古屋市 ポリ乳酸用造核剤及びポリ乳酸樹脂組成物
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
MX2011008335A (es) 2009-02-06 2011-09-06 Ortho Mcneil Janssen Pharm Novedosos compuestos heterociclicos biciclicos sustituidos como moduladores de la gamma secretasa.
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP5559309B2 (ja) 2009-05-07 2014-07-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体
SG177644A1 (en) 2009-07-15 2012-03-29 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
US9079886B2 (en) 2010-01-15 2015-07-14 Janssen Pharmaceuticals, Inc. Substituted triazole derivatives as gamma secretase modulators
US8987276B2 (en) 2011-03-24 2015-03-24 Janssen Pharmaceuticals, Inc. Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
BR112014028395B1 (pt) 2012-05-16 2022-02-01 Janssen Pharmaceuticals, Inc. Derivados 3,4-di-hidro-2h-pirido[1,2-a]pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer e composição farmacêutica que os compreende
CN104918938B (zh) 2012-12-20 2017-08-15 詹森药业有限公司 新颖的作为γ分泌酶调节剂的三环3，4‑二氢‑2H‑吡啶并[1，2‑a]吡嗪‑1，6‑二酮衍生物
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618188D0 (en) 1986-07-25 1986-09-03 Ici Plc Diamine compounds
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8813356D0 (en) 1988-06-06 1988-07-13 Ici Plc Polypeptide compounds
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
US5821241A (en) 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
US5885967A (en) 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
ES2199247T3 (es) 1994-03-11 2004-02-16 Pharmacopeia Drug Discovery, Inc. Derivados de sulfonamida y su uso.
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US6001811A (en) 1994-11-21 1999-12-14 Cortech Inc. Serine protease inhibitors--N-substituted derivatives
TW394764B (en) 1995-02-14 2000-06-21 Mitsubishi Chemcal Corp Oxygen-containing heterocyclic derivatives
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
WO1996036595A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
MX9709875A (es) 1995-06-06 1998-03-31 Pfizer N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas.
WO1996039385A1 (en) 1995-06-06 1996-12-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
AU6709596A (en) 1995-08-22 1997-03-19 Japan Tobacco Inc. Amide compounds and use of the same
EP0761680A3 (de) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazolverbindungen mit Interleukin-1beta-konvertierendes Enzym inhibierende Aktivität
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
JP2000500461A (ja) 1995-11-13 2000-01-18 スミスクライン・ビーチャム・コーポレイション 血液調節化合物
US6107309A (en) 1995-11-13 2000-08-22 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744361B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
RU2191193C2 (ru) 1996-02-13 2002-10-20 Акцо Нобель Н.В. Ингибиторы серинпротеазы
AU2277597A (en) 1996-02-23 1997-09-10 Ariad Pharmaceuticals, Inc. New inhibitors of sh2-mediated processes
TW442452B (en) 1996-03-01 2001-06-23 Akzo Nobel Nv Serine protease inhibitors having an alkynylamino side chain
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
EP1101759A4 (de) 1998-07-31 2001-12-12 Nippon Soda Co Phenylazol-derivate, verfahren zu ihrer herstellung und medikamente für hyperlipemie
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
WO2000069815A1 (en) 1999-05-13 2000-11-23 Teijin Limited Ureido-substituted cyclic amine derivatives and their use as drug
ATE308985T1 (de) 1999-05-18 2005-11-15 Teijin Ltd Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
AU5413600A (en) 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
WO2001002424A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
WO2001010439A1 (fr) 1999-08-04 2001-02-15 Teijin Limited Antagonistes d'amine cyclique ccr3
DK1088824T3 (da) 1999-09-30 2004-04-13 Pfizer Prod Inc Bicykliske pyrrolylamider som glycogen phosphorylase inhibitorer
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
KR20020070385A (ko) 2000-01-29 2002-09-06 주식회사 엘지씨아이 아릴-아미딘을 가진 팩터 Ｘａ 억제제와 그의 유도체, 및그의 프로드럭
US6797504B1 (en) 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
PT1226160E (pt) 2000-02-23 2005-04-29 Zealand Pharma As Novos peptidos antiarritmicos
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (de) 2000-03-22 2003-03-26 Pfizer Products Inc. Verwendung von Glykogen-Phosphorylase-Hemmern
WO2001094310A1 (en) 2000-06-07 2001-12-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for making bis-heterocyclic alkaloids
CA2411813A1 (en) 2000-06-14 2001-12-20 Eli Lilly And Company Tricyclic compounds as mrp1-inhibitors
IL144507A0 (en) 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
WO2002016314A1 (en) 2000-08-18 2002-02-28 H. Lundbeck A/S Substituted polyamine compounds
CA2321348A1 (en) 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
GB2369117A (en) 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
RU2003120070A (ru) 2000-12-06 2004-12-27 Авентис Фармаа Дойчланд Гмбх (De) Производные гуанидина и амидина в качестве ингибиторов фактора ха
WO2003037864A1 (fr) * 2001-10-29 2003-05-08 Japan Tobacco Inc. Compose indolique, et utilisation a des fins therapeutiques
CA2525502C (en) * 2003-05-21 2012-12-18 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途

Also Published As

Publication number Publication date
EP1725555A1 (de) 2006-11-29
US7884112B2 (en) 2011-02-08
US20080269277A1 (en) 2008-10-30
ES2353309T3 (es) 2011-03-01
WO2005085245A1 (en) 2005-09-15
EP1725555B1 (de) 2010-10-06
WO2005085245A8 (en) 2005-11-10
DE602005023965D1 (de) 2010-11-18
JP2007527904A (ja) 2007-10-04

Similar Documents

Publication Publication Date Title
ATE483708T1 (de) Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
NO20055305D0 (no) Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase
ATE424821T1 (de) Pyrrolopyridin-2-karbonsäureamide
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20044534L (no) Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
NO20082834L (no) 2-(fenyl eller heterosyklisk)-1H-fenantro[9,10-D]imidazoler som MPGES-1-inhibitorer
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
NO20051103L (no) Indol-3-karboksamider som Glukokinase-(GK)-Aktivatorer
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20053742L (no) Tri (cyclo)-substituerte amidforbindelser
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
EA200802329A1 (ru) Производные триазола ii
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20065075L (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer.
NO20092691L (no) 4-hydroksy-2-okso-2,3-dihydro-1,3-benzotiazol-7yl-forbindelser for modulering av B2-adrenoreseptoraktivitet

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties